Q1 2025 EPS Estimates for Haemonetics Co. (NYSE:HAE) Increased by Analyst

Haemonetics Co. (NYSE:HAE) – Analysts at Zacks Research raised their Q1 2025 EPS estimates for shares of Haemonetics in a research note issued to investors on Friday, April 19th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $0.95 per share for the quarter, up from their previous forecast of $0.94. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.05 EPS, FY2025 earnings at $4.16 EPS, Q1 2026 earnings at $1.23 EPS, Q2 2026 earnings at $1.17 EPS and FY2026 earnings at $4.85 EPS.

A number of other research analysts have also issued reports on the stock. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Barrington Research reissued an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th. Finally, TheStreet lowered Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th.

Haemonetics Stock Performance

Shares of HAE stock opened at $83.61 on Monday. The firm has a market capitalization of $4.25 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 1.92 and a beta of 0.36. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The business’s 50-day moving average price is $79.15 and its 200-day moving average price is $82.65. Haemonetics has a 12 month low of $70.74 and a 12 month high of $95.26.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.10. The company had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The company’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.85 earnings per share.

Hedge Funds Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Haemonetics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after acquiring an additional 27,146 shares in the last quarter. Kingdon Capital Management L.L.C. bought a new stake in Haemonetics in the third quarter worth approximately $9,952,000. Lazard Asset Management LLC boosted its holdings in shares of Haemonetics by 114.2% during the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock worth $3,452,000 after buying an additional 20,550 shares in the last quarter. Los Angeles Capital Management LLC grew its position in shares of Haemonetics by 1.1% during the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock worth $4,753,000 after buying an additional 586 shares during the period. Finally, Eagle Asset Management Inc. increased its stake in shares of Haemonetics by 2.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock valued at $24,065,000 after acquiring an additional 6,828 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.